– MT-303 is Myeloid’s second clinical in vivo mRNA CAR program; it incorporates proprietary next-generation mRNA innovations – – MT-303 programs immune cells directly in patients; the first time an in vivo CAR has been evaluated in HCC – CAMBRIDGE, Mass., July 30, 2024 /PRNewswire/ — Myeloid Therapeutics, Inc. (“Myeloid”), a clinical-stage immunology company advancing RNA […]
-Data underlie the ongoing clinical advance of MT-302, the world’s first in vivo mRNA CAR drug development candidate- -Myeloid also highlights its pioneering CRISPR-Enabled Autonomous Transposable Element (CREATE) platform technology for precision, RNA-mediated gene editing and delivery- CAMBRIDGE, Mass, May 7, 2024 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage immunology company, today announced multiple […]